Medicamen Biotec

{
  "main_header": {
    "sid": 770569,
    "name": "Medicamen Biotec",
    "stock_name": "Medicamen Biotec",
    "full_name": "Medicamen Biotech Ltd",
    "name_url": "stocks-analysis/medicamen-biotec",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "362.05",
    "chg": -11.55,
    "chgp": "-3.09%",
    "dir": -1,
    "prev_price": "373.60",
    "mcapval": "508.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531146,
    "symbol": "MEDICAMEQ",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE646B01010",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "11.18 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-biotec-770569-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mildly Bearish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-shows-mixed-technical-signals-amid-mildly-bearish-momentum-3786347",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_technicaldot_3786347.png",
        "date": "2026-01-09 08:06:19",
        "description": "Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026."
      },
      {
        "title": "Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-shows-mixed-technical-signals-amid-price-momentum-shift-3785105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_technicaldot_3785105.png",
        "date": "2026-01-08 08:15:00",
        "description": "Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Medicamen Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-3778876",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MedicamenBiotec_mojoScore_3778876.png",
        "date": "2026-01-02 10:10:03",
        "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotec-upgraded-from-strong-sell-to-sell-by-marketsmojo-3765666",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicamenBiotec_mojoScore_3765666.png",
        "date": "2025-12-22 10:10:04",
        "description": "Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory."
      },
      {
        "title": "Why is Medicamen Biotec falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-medicamen-biotec-fallingrising-3757747",
        "imagepath": "",
        "date": "2025-12-13 01:04:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Defy Broader Market Trends</strong></p>\n<p>Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.</p>\n<p>The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ..."
      },
      {
        "title": "Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotec-upgraded-from-strong-sell-to-sell-by-marketsmojo-3738147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicamenBiotec_mojoScore_3738147.png",
        "date": "2025-12-01 10:09:02",
        "description": "Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse."
      },
      {
        "title": "Medicamen Biotech Reports Strong Profit Growth Amidst Operational Efficiency Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotechs-financial-trend-improves-from-negative-to-positive-amid-strong-profit-growth-3711833",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MedicamenBiotec_fintrenddot_3711833.png",
        "date": "2025-11-18 12:01:23",
        "description": "Medicamen Biotech reported a significant increase in profit after tax for the quarter ending September 2025, reaching Rs 2.67 crore. The company also achieved its highest cash and cash equivalents at Rs 43.68 crore and net sales of Rs 47.17 crore, although it faces challenges with low return on capital employed and debtor turnover."
      },
      {
        "title": "Medicamen Biotech Q2 FY26: Profit Surge Masks Deeper Margin Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/medicamen-biotech-q2-fy26-profit-surge-masks-deeper-margin-concerns-3721211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MedicamenBiotec_quaterlyResult_3721211.png",
        "date": "2025-11-18 10:08:09",
        "description": "Medicamen Biotech Ltd., a research-led pharmaceutical company with operations spanning over 40 countries, reported a consolidated net profit of ₹2.67 crores for Q2 FY26, marking an impressive 82.88% year-on-year surge from ₹1.46 crores in the corresponding quarter last year. The sequential improvement was equally robust, with profits climbing 24.19% from ₹2.15 crores in Q1 FY26. However, the stock has struggled to capitalise on this operational momentum, declining 15.50% over the past year whilst the Sensex advanced 9.48%, resulting in a negative alpha of 24.98 percentage points."
      },
      {
        "title": "Is Medicamen Biotec overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-biotec-overvalued-or-undervalued-3706066",
        "imagepath": "",
        "date": "2025-11-17 08:10:16",
        "description": "As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms.\n\nIn comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context...."
      }
    ],
    "total": 6206,
    "sid": "770569",
    "stock_news_url": "https://www.marketsmojo.com/news/medicamen-biotech-770569"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mildly Bearish Momentum

2026-01-09 08:06:19

Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026.

Read full news article

Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift

2026-01-08 08:15:00

Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-01-02 10:10:03

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-22 10:10:04

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory.

Read full news article

Why is Medicamen Biotec falling/rising?

2025-12-13 01:04:49

Short-Term Gains Defy Broader Market Trends

Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.

The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ...

Read full news article

Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-01 10:09:02

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse.

Read full news article

Medicamen Biotech Reports Strong Profit Growth Amidst Operational Efficiency Challenges

2025-11-18 12:01:23

Medicamen Biotech reported a significant increase in profit after tax for the quarter ending September 2025, reaching Rs 2.67 crore. The company also achieved its highest cash and cash equivalents at Rs 43.68 crore and net sales of Rs 47.17 crore, although it faces challenges with low return on capital employed and debtor turnover.

Read full news article

Medicamen Biotech Q2 FY26: Profit Surge Masks Deeper Margin Concerns

2025-11-18 10:08:09

Medicamen Biotech Ltd., a research-led pharmaceutical company with operations spanning over 40 countries, reported a consolidated net profit of ₹2.67 crores for Q2 FY26, marking an impressive 82.88% year-on-year surge from ₹1.46 crores in the corresponding quarter last year. The sequential improvement was equally robust, with profits climbing 24.19% from ₹2.15 crores in Q1 FY26. However, the stock has struggled to capitalise on this operational momentum, declining 15.50% over the past year whilst the Sensex advanced 9.48%, resulting in a negative alpha of 24.98 percentage points.

Read full news article

Is Medicamen Biotec overvalued or undervalued?

2025-11-17 08:10:16

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms. In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context....

Read full news article

View All News